Maralixibat (formerly SHP-625; LUM-001; lopixibat; Livmarli) is an ileal bile acid transporter inhibitor approved for treatment of cholestatic pruritus associated with Alagille syndrome. It was approved for medical use in the United States in September 2021.

纯度：≥98%

CAS：716313-53-0